The sole FDA-approved vaccine tested so far for the disease (Sipuleucel-T, also known as ProvengeTM) only extended patient’s life by 4 months: Provenge is an autologous dendritic cell preparation from cells taken from the patient and treated with a fusion protein consisting of Granulocyte-macrophage colony-stimulating factor (GMCSF) and the antigen prostate acid phosphatase (PAP) associated with prostate tumors. The gene discussed is ACP3; the disease is prostate neoplasm.